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Endometrial cancer (EC) is the most common 
malignancy of the female genital tract. [1] It occurs 
primarily in postmenopausal women [1-5]. Overall, 
2.64% of women develop EC during their lifetime [1]. In 
patients with EC, the most common presenting 
symptom is abnormal uterine bleeding [2]. 
Based on clinical and pathological features, 
sporadic EC classified into 2 types [6 7]. Type I EC, 
represents the majority of sporadic EC cases (70-80%) 
[6, 7]. It is well differentiated, endometrioid in histology, 
has less aggressive clinical course and favourable 
prognosis [6-8]. Type II EC, represents the minority of 
sporadic EC cases (10-20%) [6, 7]. It is poorly 
differentiated, usually papillary serous or clear cell in 
histology, has aggressive clinical course and 
propensity for early spread and poor prognosis [6, 7, 9, 
10]. 
Systematic surgical staging is the baseline therapy, 
for most patients with EC [2-4, 11-15]. That therapeutic 
approach allows a more clear decision for stage related 
postoperative adjuvant therapy [12].  
In patients with EC, systematic surgical staging 
includes: total hysterectomy, bilateral salpingo-
oophorectomy, pelvic and para-aortic 
lymphadenectomy and complete resection of all 
disease [2, 12, 14, 15]. Especially in patients with type 
II EC, systematic surgical staging requires additional 
omentectomy, appendectomy and biopsy of any 
suspected lesion [15, 16]. Pelvic washings are no 
longer part of FIGO surgical staging system for EC, but 
may be reported separately [13]. 
Appropriate surgical staging provides diagnostic, 
prognostic and therapeutic benefits for women with EC 
[2-4, 12].  It facilitates targeted therapy that maximize 
survival and minimize the morbidity of over treatment  
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(radiation injury) and the effects of under treatment 
(recurrent disease, increased mortality) [12]. 
Pelvic and para-aortic lymphadenectomy is 
essential for surgical staging in patients with EC [3 4 11 
12 14]. It defines accurately the extent of disease and 
determines the prognosis of EC patients [11 15 17]. It 
is the only way to identify EC patients with stage IIIc 
disease [12, 13, 18, 19]. Also, it provides a rationale for 
the need, type and extent of postoperative adjuvant 
treatment [11, 15, 17, 20]. 
Moreover, pelvic and para-aortic lymphadenectomy 
have therapeutic benefits for patients with EC [21-23]. 
It is associated with improved survival in all patients 
with type II EC and in patients with advanced stage 
type I EC [2 21 22, 24, 25]. However it has no effect on 
survival in patients with early stage type I EC [2, 14, 26, 
27]. 
It seems that pelvic and para-aortic 
lymphadenectomy can be safely omitted in patients 
with early stage well differentiated type I EC [12, 26-
29]. However pelvic and para-aortic lymphadenectomy 
should be performed in all patients with type II EC and 
in patients with advanced stage type I EC [3, 4, 24, 30, 
31]. Also in any case of doubt, lymphadenectomy 
should be performed rather than abandoned [3, 4, 30]. 
The extension of pelvic and para-aortic lymph node 
dissection (more than 14 lymph nodes) is an 
independent risk factor for postoperative complications 
[26, 29, 32]. Especially in elderly patients and in 
patients with relevant comorbidities (obesity, diabetes, 
coronary artery disease), morbidity must be carefully 
weighed against any survival advantage [12, 32-34]. 
In most EC patients, systematic surgical staging 
performed with laparotomy [15, 35, 36]. However in EC 
patients with early stage disease, systematic surgical 
staging can be performed with minimally invasive 
techniques (laparoscopy, robotic-assisted surgery) [2, 
12, 14, 15, 35-38]. Minimally invasive surgery 
associated with smaller incisions, improved 
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visualization, shorter hospital stay, less need for 
analgesics, quicker recovery and lower risk of 
complications (blood loss, wound infection, herniation, 
ileus) [12, 14, 15, 35-38]. Moreover, it offers many 
advantages especially in overweight and elderly 
patients [12, 35-39]. Compared with laparotomy, 
minimally invasive surgery associated with similar 
overall and disease-free survival [14, 15, 35, 36]. 
However, there are relatively small differences in 
recurrence rates [35, 36]. 
Especially in EC patients with increased risk for 
recurrence or at advanced stage disease, required a 
more aggressive management with postoperative 
adjuvant radiotherapy and/or chemotherapy [2, 11, 15, 
30]. 
Postoperative adjuvant radiotherapy in EC patients 
includes vaginal brachytherapy and external 
radiotherapy [15, 40]. 
Vaginal brachytherapy in EC patients with early 
stage disease is well tolerated, reduces the risk of local 
recurrences but has no impact on overall survival [40-
43]. Moreover, it is associated with less side effects 
and better quality of life [40-43]. It is the adjuvant 
treatment of choice for intermediate risk EC patients 
(stage IA grade 3 endometrioid type EC, stage IB 
grade 1-2 endometrioid type EC) [15, 40-42, 44-46]. 
Especially for intermediate risk EC patients, vaginal 
brachytherapy is equivalent to external pelvic 
radiotherapy in achieving local control of disease [15, 
40, 41, 44, 45]. Moreover vaginal brachytherapy in 
those EC patients, have significant advantages in the 
quality of life [15, 40, 41, 44, 45]. 
External pelvic radiotherapy in EC patients with 
early stage disease, reduces the risk of local 
recurrences but has no impact on overall survival [12, 
40-42, 47, 48]. However, it is associated with significant 
morbidity and reduction in quality of life [41, 47].  It is 
used only in high-risk EC patients (stage IB grade 3 
endometrioid type EC, stage I non-endometrioid type 
EC) [15, 43-45]. 
External pelvic radiotherapy in EC patients with 
advanced stage disease, reduces the risk of local 
recurrences but has no impact on overall survival [12, 
40, 44]. 
Whole abdomen radiotherapy in EC patients with 
advanced stage disease has tolerable toxicity and may 
improve survival [49]. However, it can be used only in 
patients with completely resected disease [49]. 
Postoperative adjuvant chemotherapy is the 
mainstay of treatment for EC patients with advanced 
stage disease [2, 11, 15, 40, 50, 51]. In those EC 
patients, the most active chemotherapeutic agents are: 
taxanes, anthracyclines and platinum compounds [50 
52]. Although adjuvant chemotherapy achieve high 
response rates, it has only modest effect in progression 
free survival and overall survival [50]. Moreover 
adjuvant chemotherapy in EC patients with advanced 
stage disease, is more effective than whole abdomen 
radiotherapy [30, 53]. 
The combination of adjuvant chemotherapy and 
radiotherapy is promising in high-risk EC patients or at 
advanced stage disease [40, 50, 54]. In those EC 
patients with completely resected disease, the 
combination of adjuvant chemotherapy and 
radiotherapy reduce the risk of relapse or death and 
increase overall survival [15, 40, 55]. Moreover, the 
combination of adjuvant chemotherapy and 
radiotherapy is more effective than adjuvant 
radiotherapy alone [40, 50, 55]. 
Recent years, molecular targeted therapies have 
still shown modest effect in unselected EC patients 
[50]. They usually target the inhibition of EGFR, 
VEGFR and PI3K/PTEN/AKT/mTOR signal pathways 
[56]. 
Especially the role of ErbB-targeted therapies in EC, 
should be further investigated in clinical trials [57-64].  
Perhaps they are active as adjuvant therapy in well-
defined subgroups of type II EC patients with EGFR 
and ErbB-2 over expression [5, 57, 63, 65]. Moreover 
additional studies into the molecular pathways of EC 
development and progression, will increase our 
knowledge and lead to the discovery of new generation 
molecules with higher therapeutic efficacy [61]. 
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